Molecular Docking, Synthesis and Anti TB Activity of Heterocyclic Compounds for Resuscitation Promoting Factor B (RpfB)

Abstract

The resistance in tuberculosis is spawning very unwelcoming situations in drug discovery along with the peril for the future of public healthcare and treatment of diseases. Tuberculosis up till now has shown multi drug resistant (MDR) and extensive drug resistant (XDR) resistance to all the conventional drugs of first line second line and DOTS therapy. Within ten years the development of drugs for MDR and XDR resistant TB is inflating faster for restraining the resistance. There are many drugs to be approved and are undergoing clinical trials for approval with novel targets having greater potency and ability to defy resistance. Drug-resistant tuberculosis (TB) poses a significant challenge to the successful treatment and control of TB worldwide. Resistance to anti-TB drugs has existed since the beginning of the chemotherapy era. New insights into the resistant mechanisms to anti-TB drugs have been provided. Better understanding of drug resistance mechanisms helps in the development of new tools for the rapid diagnosis of drug-resistant TB. There is also a pressing need in development of new drugs with novel targets to improve the current treatment of TB and to prevent the emergence of drug resistance in Mycobacterium tuberculosis. The anti-TB drug resistance mechanisms, furnishes some possible novel drug targets in the development of new agents for TB therapy and usefulness of known targets to develop new anti-TB drugs. Whole genome sequencing is currently an advanced technology to uncover drug resistance mechanisms in M. tuberculosis. However, further research is required to unravel the significance of some newly discovered gene mutations in their contribution to drug resistance.